siRNA

Vivatides Therapeutics Raises $54M to Expand RNA Therapies

Boston, Massachusetts | April 13, 2026 Vivatides Therapeutics has announced the successful completion of a $54 million oversubscribed Series...

By cGxPwire Editor
April 14, 2026

Bio-Pharma

Sarepta Reports Breakthrough siRNA Data in FSHD, DM1

CAMBRIDGE, Massachusetts, March 25, 2026 Sarepta Therapeutics has announced first clinical data from its next-generation siRNA pipeline, demonstrating robust...

By cGxPwire Editor
March 26, 2026

Bio-Pharma

Junevity Secures $20M to Advance siRNA Cell-Reprogramming Platform

SAN FRANCISCO, December 3, 2025 — Junevity today announced the expansion of its seed funding round to $20 million...

By cGxPwire Editor
December 4, 2025

Bio-Pharma

Capricor Unveils Scalable Exosome Platform for Oligonucleotide Delivery

San Diego, California, November 24, 2025 — Capricor Therapeutics, Inc. announced new data at the AAEV 2025 meeting that...

By cGxPwire Editor
November 24, 2025

Bio-Pharma

Phio to Present INTASYL siRNA Advances at ATUSA 2025

Dateline IntroductionNovember 17, 2025 — Marlborough, Massachusetts — Phio Pharmaceuticals Corp., a clinical-stage biopharmaceutical company advancing RNA-based immuno-oncology therapeutics,...

By cGxPwire Editor
November 18, 2025

Find Jobs Across Pharma, Biotech & Life Sciences

Discover verified job opportunities from top companies worldwide. Apply easily and grow your career in the life sciences industry.

Bio-Pharma

Phio Pharmaceuticals Advances siRNA Immunotherapy in Skin Cancer with INTASYL PH-762

Dateline — King of Prussia, Pennsylvania, November 7, 2025:Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has announced new clinical data from...

By cGxPwire Editor
November 9, 2025

Bio-Pharma

Phio Pharmaceuticals Strengthens Governance with New Lead Director

King of Prussia, Pennsylvania – October 31, 2025 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing...